Compass pathways stock forecast.

COMPASS Pathways (NASDAQ: CMPS) has seen its earnings outlook for FY2023 revised by Cantor Fitzgerald. The equities researchers at Cantor Fitzgerald have raised their EPS estimates, predicting that the company will now earn ($2.08) per share for the year, up from their previous forecast of ($2.24).Nov 13, 2023 · Future criteria checks 0/6. COMPASS Pathways's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 82.4% per year. EPS is expected to grow by 6.1% per annum. Return on equity is forecast to be -82.5% in 3 years. From this work, Compass Pathways in my opinion is trading at around its current market price. Figure 6: Valuation of Compass Pathways (Source: Author's valuation work, using base data from CMPS' 10-K)COMPASS Pathways (CMPS) Fundamentals Checker. Financial metrics are used to evaluate financial stability which helps analysts determine if COMPASS Pathways is undervalued compared to its fair value. A company's financial health can strongly influence the stock forecast.Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. Close Trending Tickers bar

(Note: COMPASS stock price on Nasdaq jumped between June 30 and July 5, going from $8.10 to currently trading at $8.80 following highest at $9.02 also today, July 5 shortly after opening and ...

LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation, today announced that Co-founder and Chief Innovation Officer Dr. Ekaterina Malievskaia will step down from her executive role …

That's true for all of the existing public psychedelic biotechs engaged in drug development, including such industry leaders as Compass Pathways (CMPS-2.26%) and Atai Life Sciences (ATAI-1.51%).17 ต.ค. 2565 ... Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics.Stock Price Forecast. The 9 analysts offering 12-month price forecasts for Compass Inc have a median target of 2.70, with a high estimate of 5.00 and a low estimate of 2.00. The median estimate ...See COMPASS Pathways plc (CMPS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Shares of the Peter Thiel -backed psychedelic start-up Atai Life Sciences jumped Friday on their first day of trading on Wall Street. The newly listed Nasdaq stock opened up 40% before pulling ...

CMPS Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $50.17 …

View Our Latest Research Report on COMPASS Pathways. COMPASS Pathways Price Performance. COMPASS Pathways stock opened at $6.01 on Friday. The firm has a market cap of $372.02 million, a P/E ratio of -2.32 and a beta of 2.56. The stock’s 50 day moving average is $6.75 and its 200 day moving average is $7.90.

COMPASS Pathways is a market leader in the listed psychedelics space and the company has made significant advances over the last few years. COMPASS is burning through cash at a high rate relative ...Dec 1, 2023 · 8 Wall Street research analysts have issued 1-year target prices for Compass' shares. Their COMP share price targets range from $2.25 to $5.00. On average, they expect the company's stock price to reach $3.39 in the next twelve months. This suggests a possible upside of 47.2% from the stock's current price. And the biotechnology industry's average price-to-sales multiple is 4.7. Thus, if Compass manages to capture a mere 10% of that per year, it could be bringing in $139 million in revenue. Assuming ...COMPASS Pathways (NASDAQ: CMPS) has seen its earnings outlook for FY2023 revised by Cantor Fitzgerald. The equities researchers at Cantor Fitzgerald have raised their EPS estimates, predicting that the company will now earn ($2.08) per share for the year, up from their previous forecast of ($2.24).UK-based COMPASS Pathways recently published data from its Phase IIb trials, with COMP360 psilocybin therapy for treatment-resistant depression. This follows the release of the design for the company’s pivotal Phase III trials, the first-ever Phase III psilocybin therapy trial and the final studies prior to market approval. With the treatment’s …

Nonetheless, Atai remains one of the leaders in the psychedelics segment of the biotech industry, and it holds a 22.4% stake in Compass Pathways, which is one of the other leaders. So if Compass ...WebCOMPASS Pathways PLC ADR analyst ratings, historical stock prices, earnings estimates & actuals. CMPS updated stock price target summary. Current. -$0.61. 1 Month Ago. -$0.60. 3 Months Ago. -$0.65. COMPASS Pathways PLC ADR analyst estimates, including CMPS earnings per share estimates and analyst recommendations.WebWe note that hedge funds don't have a meaningful investment in COMPASS Pathways. Atai Life Sciences N.V. is currently the company's largest shareholder with 19% of shares outstanding. The second ...Atai bought another 619,095 Compass Pathways shares in recent days, taking its stake in the company from 19.4% to 20.8%. The new shares were bought at around $31 each, meaning Atai paid around $12 ...

Company's cash position stands at $248.0 million with a net loss of $33.4 million for Q3 2023. Get the latest COMPASS Pathways plc (CMPS) stock news and headlines to help you in your trading and ...

What happened. Compass Pathways ( CMPS 6.18%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ...WebReal-time share price updates and latest news for Compass Pathways ADR (NASDAQ:CMPS). Compare across sectors, industries & regions.COMPASS Pathways Stock Price, News & Analysis (NASDAQ:CMPS) $5.98 +0.05 (+0.84%) (As of 04:00 PM ET) Compare Today's Range $5.91 $6.56 50-Day Range $5.27 $7.96 52-Week Range $5.01 $11.48 Volume 900,582 shs Average Volume 342,967 shs Market Capitalization $370.16 million P/E Ratio N/A Dividend Yield N/A Price Target $46.83Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ...*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. COMPASS Pathways Analyst Opinions. All. All ...CMPS Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $50.17 with a high forecast of $120.00 and a low forecast of $21.00. The average price target represents a 832.53% change from the last price of $5.38.An easy way to get COMPASS Pathways Plc - American Depository Shares real-time prices. View live CMPS depositary receipt chart, financials, and market news.Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ... A high-level overview of COMPASS Pathways plc (CMPS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. We explain how to buy Compass Pathways Plc stock, compare the best stock trading platforms and use a detailed analysis to learn about (CMPS).

COMPASS Pathways EBIT Forecast for 2023 - 2025 - 2030. In the last year, COMPASS Pathways's EBIT has grown from $-47.15M to $-73.57M – a 56.03% increase. For the following year, the 0 analysts predict that COMPASS Pathways's EBIT will drop by 35.91%, reaching $-47.15M. In 2030, the professionals' prediction is that CMPS's EBIT will decrease ...

The share price of Square, Inc. (SQ) now. What analysts predict: $71.11. 52-week High/Low: $89.97 / $38.85. 50/200 Day Moving Average: $47.45 / $61.43. This figure corresponds to the Average Price over the previous 50/200 days. For Square stocks, the 50-day moving average is the support level today. For Square stocks, the 200-day …

On average, Wall Street analysts predict. that Compass Pathways's share price could reach $57.25 by Aug 22, 2024. The average Compass Pathways stock price prediction forecasts a potential upside of 857.36% from the current CMPS share price of $5.98. We explain how to buy Compass Pathways Plc stock, compare the best stock trading platforms and use a detailed analysis to learn about (CMPS).9 พ.ย. 2564 ... Compass Pathways CEO on mushroom-based therapy for depression ... Global Business and Financial News, Stock Quotes, and Market Data and Analysis.Compass Pathways has released the strongest evidence yet that psilocybin can improve outcomes in patients with treatment-resistant depression, linking its COMP360 candidate to a sharp improvement ...Aug 22, 2023 · COMPASS Pathways-stock; ... Compass Pathways has an average price target of $56.82 with a high of $120.00 and a low of $21.00. ... Some analysts will also offer forecasts for metrics like growth ... COMPASS PATHWAYS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie COMPASS Pathways PLC (spons. ADRs) | A2QCDR | CMPS | US20451W1018 Compass Pathways. Compass Pathways’ roots go back to 2015, when George Goldsmith and Ekaterina Malievskaia founded a nonprofit organization, the Compass Trust Limited, to support research and ...COMPASS Pathways plc (CMPS) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 5.93 -0.05 (-0.84%) At close: 04:00PM EST. 6.03 +0.10 …For COMPASS Pathways plc stock forecast for 2023, 2 predictions are offered for each month of 2023 with average COMPASS Pathways plc stock forecast of $5.33, a high forecast of $5.36, and a low forecast of $5.3. The average COMPASS Pathways plc stock forecast 2023 represents a 0.88% increase from the last price of $5.28499984741211.In September of 2020, at $17 per share, Compass Pathways stock completed its public offering. Since the initial offering, CMPS has traded as high as $60 per share and seems to average out in the ...

Low. $35.00. Average. $71.83. Current Price. $60.31. Overview. Research & Ratings. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume ...In the last 3 months, 4 analysts have offered 12-month price targets for Compass Pathways. The company has an average price target of $53.75 with a high of $120.00 and a low of $19.00.Jul 2, 2023 · COMPASS Pathways is a mental healthcare company that specializes in psilocybin therapy. Read more to see my thoughts on CMPS stock and why it is a Hold. ... CMPS Stock Forecast. Aug 16, 2023 · Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select ... Instagram:https://instagram. celine dion concert 2023options calcultorpreferred dividend stocksbest bank mobile Canaccord Genuity analyst Sumant Kulkarni gives the biotech company an $80 price target....CMPS Compass Pathways (CMPS) has grabbed the interest of Canaccord Genuity analyst Sumant Kulkarni, who gave the biotech company an $80 price target.... gold royalty stockgrowth stocks under dollar10 (Note: COMPASS stock price on Nasdaq jumped between June 30 and July 5, going from $8.10 to currently trading at $8.80 following highest at $9.02 also today, July 5 shortly after opening and ...Web where can i trade futures 3 พ.ค. 2564 ... Did you miss out on being an early investor in the Cannabis Boom? Investing in Compass Pathways stock ($CMPS) may be your golden ticket.May 25, 2021 · Learn More. Market Cap. (-2.86%) -$0.17. Current Price. The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic ...